Biotech Tracker
Trial resultsNov 9, 20202178 days ago

BNT162b2 Phase 3 interim: >90% efficacy

BioNTech reported results from its Phase 3 study of BNT162b2 (Comirnaty) for COVID-19 prevention on Nov 9, 2020. The linked source has what the numbers showed.

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary

DetailsClinical trial results · also called: readout / topline data
Company
BioNTech SE BNTX
Drug
BNT162b2 (Comirnaty)
For
COVID-19 prevention
Stage
Phase 3 · the last stage before a drug can be approved
When
Nov 9, 2020
Source note
Pfizer/BioNTech announced first interim efficacy analysis of their COVID-19 vaccine trial.
Checked
Checked by a person when it was added
Check the sourcesdon’t take our word for it
BioNTech SE
BNTX
5 upcoming · 7 past catalysts
More from BNTX
Trial resultsBNTXBioNTech2026

BioNTech expects to report results from its Phase 2/3 study of Pumitamig (BNT327) for Solid tumors (NSCLC, SCLC, TNBC, CRC, gastric, others) during 2026 (no exact date yet). Phase 2/3 is a combined mid- to late-stage study.

More details
Entry
Multiple pumitamig combination data readouts expected in 2026 · Clinical trial results (readout / topline data)
Drug
Pumitamig (BNT327)
For
Solid tumors (NSCLC, SCLC, TNBC, CRC, gastric, others)
Stage
Phase 2/3 · a combined mid- to late-stage study
When
2026 · the company gave a window, not a day
Source note
BioNTech Aug 4, 2026 Q2 release; company guides only to '2026' for further pumitamig combination readouts.
Checked
Checked by a person when it was added
Verify it

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Trial resultsBNTXBioNTechH2 2026

BioNTech expects to report results from its Phase 3 study of gotistobart (BNT316/ONC-392, anti-CTLA-4) for Squamous non-small cell lung cancer in the second half of 2026 (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.

More details
Entry
Gotistobart (BNT316) Phase 3 interim analysis in squamous NSCLC · Clinical trial results (readout / topline data)
Drug
gotistobart (BNT316/ONC-392, anti-CTLA-4)
For
Squamous non-small cell lung cancer
Stage
Phase 3 · the last stage before a drug can be approved
When
H2 2026 · the company gave a window, not a day
Source note
BioNTech guidance: 'First interim analysis from Stage 2 of the two-stage Phase 3 clinical trial is expected in 2026' — encoded H2 2026 as the remaining window of the guided year.
Checked
Checked by a person when it was added
Verify it

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Trial resultsBNTXBioNTechH2 2026

BioNTech expects to report results from its Phase 2/3 study of BNT113 (FixVac mRNA immunotherapy) + pembrolizumab for Unresectable recurrent/metastatic PD-L1+, HPV16+ head and neck squamous cell carcinoma in the second half of 2026 (no exact date yet). Phase 2/3 is a combined mid- to late-stage study.

More details
Entry
BNT113 AHEAD-MERIT Phase 3 first interim analysis in HPV16+ head and neck cancer · Clinical trial results (readout / topline data)
Drug
BNT113 (FixVac mRNA immunotherapy) + pembrolizumab
For
Unresectable recurrent/metastatic PD-L1+, HPV16+ head and neck squamous cell carcinoma
Stage
Phase 2/3 · a combined mid- to late-stage study
When
H2 2026 · the company gave a window, not a day
Source note
BioNTech FY2025 report (March 2026): 'data are expected in 2026 from the first interim analysis of the Phase 3 part'; encoded H2 2026 as the remaining window of the guided year.
Checked
Checked by a person when it was added
Verify it

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

MilestoneBNTXBioNTechH2 2026

Planned BLA filing for trastuzumab pamirtecan (BNT323), expected in the second half of 2026 (no exact date yet). A company milestone for BioNTech (trastuzumab pamirtecan (BNT323/DB-1303) for HER2-expressing endometrial cancer (initial filing indication; breast strategy pending data)): a step in the program rather than a decision or a data readout.

More details
Entry
Planned BLA filing for trastuzumab pamirtecan (BNT323) · Company milestone
Drug
trastuzumab pamirtecan (BNT323/DB-1303)
For
HER2-expressing endometrial cancer (initial filing indication; breast strategy pending data)
Stage
BLA preparation (Breakthrough Therapy designation)
When
H2 2026 · the company gave a window, not a day
Source note
BioNTech and DualityBio 'plan to file a biologics license application... in 2026'; optimal regulatory path across endometrial and breast indications to be finalized on complete data. Encoded H2 2026 (remaining window).
Checked
Checked by a person when it was added
Verify it

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Trial resultsBNTXBioNTechQ4 2026

BioNTech expects to report results from its Phase 3 study of trastuzumab pamirtecan (BNT323/DB-1303, HER2 ADC) for HR+/HER2-low metastatic breast cancer in Q4 2026 (Oct–Dec) (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.

More details
Entry
Trastuzumab pamirtecan (BNT323) DYNASTY-Breast02 primary analysis · Clinical trial results (readout / topline data)
Drug
trastuzumab pamirtecan (BNT323/DB-1303, HER2 ADC)
For
HR+/HER2-low metastatic breast cancer
Stage
Phase 3 · the last stage before a drug can be approved
When
Q4 2026 · the company gave a window, not a day
Source note
BioNTech Q2 2026 press release: 'Primary analysis is expected in the fourth quarter 2026' — one of three guided 2026 late-stage readouts (immunomodulator, ADC, mRNA immunotherapy).
Checked
Checked by a person when it was added
Verify it

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page